|Bid||1,440.00 x 0|
|Ask||1,440.50 x 0|
|Day's range||1,419.00 - 1,446.50|
|52-week range||790.00 - 2,246.40|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||22.97|
|Earnings date||18 Sep 2020 - 22 Sep 2020|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||17 Oct 2019|
|1y target est||1,664.33|
Smiths Detection, a global leader in detection and screening technologies, today confirmed that it has completed the acquisition of PathSensors, a leading bio-technology solutions and environmental-testing company, based in Baltimore, MD, USA.
Smiths Group plc (LON:SMIN) shareholders should be happy to see the share price up 14% in the last quarter. But that...
Smiths Detection today announces that it has partnered with Attomarker Ltd, a multiplex blood-testing technology company spun out of the University of Exeter, to help produce a robust and accurate COVID-19 antibody-testing device that could represent an evolution in rapid and precise COVID-19 antibody testing. The Medicines and Healthcare Products Regulatory Agency (MHRA) has already approved Attomarker’s Triple Antibody Test for NHS use in the UK.